While therapies targeting SIRPα do not cause direct cytotoxicity on tumor cells, CD47-targeting therapies may induce phagocytosis and direct cytotoxicity of CD47+ cancer cells [198] by engaging activating Fcγ receptors on macrophages and NK cells. Here, SIRPA is linked to cancer.